Skip to content
lifestyle.briefmobile.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Insilico Medicine
Insilico Medicine to Announce 2025 Financial Results on March 30, 2026
May 3, 2026
Insilico and TaiGen Achieve Milestone in Collaboration: Out-Licensed CKD Anemia Candidate ISM4808 Completes first human enrollment and dosing in Phase I clinical trial
May 1, 2026
Insilico Medicine and Liquid AI Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for Drug Discovery
May 1, 2026
AI-Powered R&D Acceleration: Insilico Medicine and CMS announce multiple collaborations in central nervous system and autoimmune diseases
March 9, 2026
Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development – Oncology
March 9, 2026
Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications
March 9, 2026
Insilico Medicine Receives USD 5million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501
February 3, 2026
Up to 31.3% Body Weight Loss, Insilico Medicine Nominates AI-Powered GIPR Antagonist ISM0676 as Preclinical Candidate, Showing Synergistic Efficacy in Combination Therapy
January 29, 2026
←
Previous Page
1
2
3